Terms: = Prostate cancer AND NRG1, ENSG00000157168, 3084, SMDF, NDF, HRGA, HRG1, HGL, GGF2, GGF, ARIA
27 results:
1. Redesign of radiotherapy for prostate cancer: a proposal for universal healthcare systems.
Beck da Silva Etges AP; de Lara LR; Sapper SL; Frankenberg Berger AV; Streck M; Zardo L; Linhares A; Nassif M; Zanotto A; Pereira Lima MN; Vargas R; Polanczyk CA
J Comp Eff Res; 2023 Dec; 12(12):e230023. PubMed ID: 37916706
[No Abstract] [Full Text] [Related]
2. Error mitigation enables PET radiomic cancer characterization on quantum computers.
Moradi S; Spielvogel C; Krajnc D; Brandner C; Hillmich S; Wille R; Traub-Weidinger T; Li X; Hacker M; Drexler W; Papp L
Eur J Nucl Med Mol Imaging; 2023 Nov; 50(13):3826-3837. PubMed ID: 37540237
[TBL] [Abstract] [Full Text] [Related]
3. Comprehensive analysis of tumor mutation burden and immune microenvironment in prostate cancer.
Liao J; Ye Y; Xu X
Clin Transl Oncol; 2022 Oct; 24(10):1986-1997. PubMed ID: 35732871
[TBL] [Abstract] [Full Text] [Related]
4. HER3 Is an Actionable Target in Advanced prostate cancer.
Gil V; Miranda S; Riisnaes R; Gurel B; D'Ambrosio M; Vasciaveo A; Crespo M; Ferreira A; Brina D; Troiani M; Sharp A; Sheehan B; Christova R; Seed G; Figueiredo I; Lambros M; Dolling D; Rekowski J; Alajati A; Clarke M; Pereira R; Flohr P; Fowler G; Boysen G; Sumanasuriya S; Bianchini D; Rescigno P; Aversa C; Tunariu N; Guo C; Paschalis A; Bertan C; Buroni L; Ning J; Carreira S; Workman P; Swain A; Califano A; Shen MM; Alimonti A; Neeb A; Welti J; Yuan W; de Bono J;
Cancer Res; 2021 Dec; 81(24):6207-6218. PubMed ID: 34753775
[TBL] [Abstract] [Full Text] [Related]
5. Technical Note: A standardized automation framework for monitoring institutional radiotherapy protocol compliance.
Quirk S; Lovis J; Stenhouse K; Van Dyke L; Roumeliotis M; Thind K
Med Phys; 2021 May; 48(5):2661-2666. PubMed ID: 33619728
[TBL] [Abstract] [Full Text] [Related]
6. Pattern of care in radiotherapy at a University Hospital in Spain: the RENORT project.
López-Torrecilla J; González Sanchis D; Granero Cabañero D; García Miragall E; Almendros Blanco P; Hernandez Machancoses A; Brualla González L; Pastor Peidro J; Gordo Partearroyo JC; Rosello Ferrando J
Clin Transl Oncol; 2021 Aug; 23(8):1657-1665. PubMed ID: 33586123
[TBL] [Abstract] [Full Text] [Related]
7. Identification of tumors with nrg1 rearrangement, including a novel putative pathogenic UNC5D-nrg1 gene fusion in prostate cancer by data-drilling a de-identified tumor database.
Ptáková N; Martínek P; Holubec L; Janovský V; Vančurová J; Grossmann P; Navarro PA; Rodriguez Moreno JF; Alaghehbandan R; Hes O; Májek O; Pešek M; Michal M; Ondič O
Genes Chromosomes Cancer; 2021 Jul; 60(7):474-481. PubMed ID: 33583086
[TBL] [Abstract] [Full Text] [Related]
8. Microenvironment-Mediated Resistance to Anti-Androgen Therapy.
Orme JJ; Huang H
Cancer Cell; 2020 Aug; 38(2):155-157. PubMed ID: 32781041
[TBL] [Abstract] [Full Text] [Related]
9. Tumor Microenvironment-Derived nrg1 Promotes Antiandrogen Resistance in prostate cancer.
Zhang Z; Karthaus WR; Lee YS; Gao VR; Wu C; Russo JW; Liu M; Mota JM; Abida W; Linton E; Lee E; Barnes SD; Chen HA; Mao N; Wongvipat J; Choi D; Chen X; Zhao H; Manova-Todorova K; de Stanchina E; Taplin ME; Balk SP; Rathkopf DE; Gopalan A; Carver BS; Mu P; Jiang X; Watson PA; Sawyers CL
Cancer Cell; 2020 Aug; 38(2):279-296.e9. PubMed ID: 32679108
[TBL] [Abstract] [Full Text] [Related]
10. Mapping cancer incidence across Western Victoria: the association with age, accessibility, and socioeconomic status among men and women.
Cowdery SP; Sajjad MA; Holloway-Kew KL; Mohebbi M; Williams LJ; Kotowicz MA; Livingston PM; Khasraw M; Hakkennes S; Dunning TL; Brumby S; Page RS; Sutherland AG; Brennan-Olsen SL; Berk M; Campbell D; Pasco JA
BMC Cancer; 2019 Sep; 19(1):892. PubMed ID: 31492163
[TBL] [Abstract] [Full Text] [Related]
11. Exploring targets of TET2-mediated methylation reprogramming as potential discriminators of prostate cancer progression.
Kamdar S; Isserlin R; Van der Kwast T; Zlotta AR; Bader GD; Fleshner NE; Bapat B
Clin Epigenetics; 2019 Mar; 11(1):54. PubMed ID: 30917865
[TBL] [Abstract] [Full Text] [Related]
12. Development of a Radiation Oncology-Specific Prospective Data Registry for Research and Quality Improvement: A Clinical Workflow-Based Solution.
Chen AM; Kupelian PA; Wang PC; Steinberg ML
JCO Clin Cancer Inform; 2018 Dec; 2():1-9. PubMed ID: 30652556
[TBL] [Abstract] [Full Text] [Related]
13. Real world evidence: Abiraterone use post-docetaxel in metastatic castrate-resistant prostate cancer.
Shivji A; Ali R; North S; Sawyer M; Ghosh S; Chambers C
J Oncol Pharm Pract; 2019 Sep; 25(6):1293-1300. PubMed ID: 29945535
[TBL] [Abstract] [Full Text] [Related]
14. Response to ERBB3-Directed Targeted Therapy in
Drilon A; Somwar R; Mangatt BP; Edgren H; Desmeules P; Ruusulehto A; Smith RS; Delasos L; Vojnic M; Plodkowski AJ; Sabari J; Ng K; Montecalvo J; Chang J; Tai H; Lockwood WW; Martinez V; Riely GJ; Rudin CM; Kris MG; Arcila ME; Matheny C; Benayed R; Rekhtman N; Ladanyi M; Ganji G
Cancer Discov; 2018 Jun; 8(6):686-695. PubMed ID: 29610121
[No Abstract] [Full Text] [Related]
15. Biopsy Perineural Invasion in prostate cancer Patients Who Are Candidates for Active Surveillance by Strict and Expanded Criteria.
Turner RM; Yecies TS; Yabes JG; Ristau BT; Woldemichael E; Davies BJ; Jacobs BL; Nelson JB
Urology; 2017 Apr; 102():173-177. PubMed ID: 27864108
[TBL] [Abstract] [Full Text] [Related]
16. Acknowledging unreported problems with active surveillance for prostate cancer: a prospective single-centre observational study.
Hefermehl LJ; Disteldorf D; Lehmann K
BMJ Open; 2016 Feb; 6(2):e010191. PubMed ID: 26888730
[TBL] [Abstract] [Full Text] [Related]
17. Are pitch and roll compensations required in all pathologies? A data analysis of 2945 fractions.
Mancosu P; Reggiori G; Gaudino A; Lobefalo F; Paganini L; Palumbo V; Stravato A; Tomatis S; Scorsetti M
Br J Radiol; 2015; 88(1055):20150468. PubMed ID: 26393283
[TBL] [Abstract] [Full Text] [Related]
18. CD74-nrg1 fusions in lung adenocarcinoma.
Fernandez-Cuesta L; Plenker D; Osada H; Sun R; Menon R; Leenders F; Ortiz-Cuaran S; Peifer M; Bos M; Daßler J; Malchers F; Schöttle J; Vogel W; Dahmen I; Koker M; Ullrich RT; Wright GM; Russell PA; Wainer Z; Solomon B; Brambilla E; Nagy-Mignotte H; Moro-Sibilot D; Brambilla CG; Lantuejoul S; Altmüller J; Becker C; Nürnberg P; Heuckmann JM; Stoelben E; Petersen I; Clement JH; Sänger J; Muscarella LA; la Torre A; Fazio VM; Lahortiga I; Perera T; Ogata S; Parade M; Brehmer D; Vingron M; Heukamp LC; Buettner R; Zander T; Wolf J; Perner S; Ansén S; Haas SA; Yatabe Y; Thomas RK
Cancer Discov; 2014 Apr; 4(4):415-22. PubMed ID: 24469108
[TBL] [Abstract] [Full Text] [Related]
19. Unintended effects of statins in men and women in England and Wales: population based cohort study using the QResearch database.
Hippisley-Cox J; Coupland C
BMJ; 2010 May; 340():c2197. PubMed ID: 20488911
[TBL] [Abstract] [Full Text] [Related]
20. HER3 is required for the maintenance of neuregulin-dependent and -independent attributes of malignant progression in prostate cancer cells.
Soler M; Mancini F; Meca-Cortés O; Sánchez-Cid L; Rubio N; López-Fernández S; Lozano JJ; Blanco J; Fernández PL; Thomson TM
Int J Cancer; 2009 Dec; 125(11):2565-75. PubMed ID: 19530240
[TBL] [Abstract] [Full Text] [Related]
[Next]
